International in vitro diagnostic firm, Adaltis has an ambitious plan to leverage its experience in Europe to become the leading provider of in vitro diagnostic products in emerging markets, with a particular focus on China. In a strategic move, the company has signed a distribution agreement with Europe-based bioMerieux in China for its infectious diseases products. Adaltis will manufacture and supply specific infectious diseases products to bioMerieux, who will distribute the products through their distribution network in Asia.
This agreement will leverage the high quality of Adaltis' products and the distribution network of bioMerieux in order to effectively increase Adaltis' penetration of key markets. The terms of the agreement were no disclosed.
"Adaltis is pleased to be associated with bioMerieux which is an internationally recognized leader in the in vitro diagnostic industry. This agreement with bioMerieux demonstrates a clear validation in Adaltis' capabilities to deliver high-quality products from our state-of-the-art manufacturing facility in Shanghai, China. Adaltis will continue its development of innovative diagnostic products and will continue to search for key partners to distribute these products as we expand our geographic reach," said Dr Raymond Tong, Chief Operation Officer of Adaltis, who is based in China.